PolyU joins forces with Axis Therapeutics, a newly established joint venture by two global biopharmaceutical companies – Athenex, Inc. and Xiangxue Pharmaceutical, to foster the research and development of translational medicine by setting up a Joint Center for Immunotherapy. The Center is set to conduct collaborative research on cancer immunotherapy, with an aim to develop new cancer treatments. PolyU will provide full support for the research on novel technologies and genetics models to develop cancer immunotherapy technologies, and is committed in transferring pioneering research to real-life applications for the benefits of mankind.
 |
 |
